Endovascular repair of AAA, first reported by Parodi et al16 in 1991, is here to stay. This procedure, wherein an "endograft" is deployed from within the AAA sac via catheter manipulation from a remote (usually transfemoral) access site, has been developed and applied at a "future shock" pace during the past 5 years. While this technology will remain in evolution during the next decade, and the long-term follow-up studies necessary to document its durability are as yet unavailable, the only remaining issue is what percentage of AAAs will be treated with endovascular repair once its evolution is complete. Short-term feasibility, safety, and even efficacy are typically satisfactory in initial experience. Thereafter, patient selection considerations and device and protocol constraints become paramount. The European experience has evolved at an unbridled pace, whereas every potentially commercially available device in the United States has been introduced in the form of clinical trials sponsored by the US Food and Drug Administration, with the obvious advantage of rigorous data collection and the use of concurrent, if not randomized, controls. Patient selection criteria for endovascular repair are largely anatomy driven or a function of prohibitive operative risk for conventional repair. The percentage of AAAs treatable with endovascular repair will vary greatly in accordance with the patient's candidacy for open operative repair. When rigid anatomical selection criteria are maintained, such as in protocol trials, that percentage will be in the 20% to 30% range. When high-risk patients (such that open repair is not feasible) are evaluated for endovascular repair, this percentage will climb to the 80% to 90% range and, in our experience, often requires the application of "homemade" devices; ie, those with modifications to minimize the anatomical constraints applied to protocol devices.